Ed Quilty, CEO Of Derma Sciences, Outlines His Strategy To Build A Premier Wound Healing Company
- DSCI is a pure play investment opportunity for the treatment of diabetic foot ulcers; the incidence for which is about 1.2 million cases per year.
- DSCI's products are applicable to 300,000 to 500,000 cases which develop into serious conditions for which the treatment cost is $20,000 to $40,000.
- Its Advanced Wound Care Products are projected to have sales of $45 in 2014 and are growing at 30% per year justifying much of the current $280 million market capitalization.
- There is not much in the stock price for DSC-127, a potential blockbuster drug in phase 3 that will report data in mid-2015.